CVC WG Monthly Meeting Summary - Novavax COVID-19 vaccine concept created & other updates

Hi everyone,

Thank you for attending the CVC Monthly Meeting last week. Please find below a summary of the meeting and action items.

The next CVC Working Group meeting will take place on Thursday, April 29, 2021 from 2:00-3:00pm EST. Note that you must register in advance for this meeting (registration link:
infoway-inforoute.zoom.us/meeting/register/tJMrdOmqrT4uG9dhwGhBAu7UOwY0eybX8fAZ)

COVID-19 Terminology Discussion

• A SNOMED-CT concept has been created for Novavax (link to RFC: informs.infoway-inforoute.ca/browse/SCT-11285?filter=-3):
• ConceptID: 29171000087106 | FSN: NOVAVAX COVID-19 VACCINE 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug) | PT: COVID-19 NOVAVAX COVID-19 VACCINE NOV
• For the generic agent - COVID-19 protein subunit vaccine (link to RFC: informs.infoway-inforoute.ca/browse/SCT-11336?filter=-3_), CHI has indicated that a SNOMED-CT code will be available in mid-April when the database is re-opened.
• Discussion: Should we be future proofing COVID-19 trade name terminology now to support a manufacturer putting out new COVID-19 vaccine products of different types in the future? - CVC team and stakeholders to take back for discussion, to be re-visited at next CVC meeting.

RFC - Rabavert (Request from Ontario)

• RFC to update the MAH for Rabavert has been completed (link to RFC: informs.infoway-inforoute.ca/browse/SCT-11339?filter=-2)
• Updated FSN: RabAvert 2.5 international units per milliliter powder for solution for injection Bavarian Nordic A/S (real clinical drug)
• Updated English PT: Rab RabAvert BN
• Updated French PT: Rage RabAvert BN

WHO Smart Vaccine Certificate Draft Standard Discussion

• The WHO has posted an RC1 for public comment of the Smart Vaccination Certificate (www.who.int/news-room/articles-detail/call-for-public-comments-interim-guidance-for-developing-a-smart-vaccination-certificate-release-candidate-1). Stakeholders are invited to provide feedback on this document.
• If stakeholders would like to further discuss this in the next CVC working group meeting, please submit an agenda item to the CVC team.

CVC Working Group Terms of Reference - Feedback

• To better define the scope, structure and operations of the CVC Working Group, a CVC Working Group Terms of Reference has been drafted (this can be found on the PHS Community > Documents > Meeting Information > 2021). Feedback is very welcome; please submit your questions or comments to the CVC team by Thursday, April 15th.

CVC Release Update

• CVC Version 1.1.8 was released on March 30th, which included updated COVID-19 terminology. The latest version can be found on www.cvc.canimmunize.ca.
• The next CVC release is scheduled for April 13th. This will include lot/expiry information for COVID-19 vaccines (beyond March 29th), as well as lot/expiry information for all vaccines up until March 31, 2021.
• During the COVID-19 vaccine roll-out, new releases of the CVC will be published without a prerelease. Please let us know if you have any questions or concerns with this approach.

Please let me know if you have any questions, comments, or items to add to the next meeting's agenda.

Best,
Taylor